JP2021528439A5 - - Google Patents

Info

Publication number
JP2021528439A5
JP2021528439A5 JP2020571532A JP2020571532A JP2021528439A5 JP 2021528439 A5 JP2021528439 A5 JP 2021528439A5 JP 2020571532 A JP2020571532 A JP 2020571532A JP 2020571532 A JP2020571532 A JP 2020571532A JP 2021528439 A5 JP2021528439 A5 JP 2021528439A5
Authority
JP
Japan
Prior art keywords
seq
composition according
human
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528439A (ja
JP7513530B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/066700 external-priority patent/WO2019243636A1/en
Publication of JP2021528439A publication Critical patent/JP2021528439A/ja
Publication of JP2021528439A5 publication Critical patent/JP2021528439A5/ja
Priority to JP2024103927A priority Critical patent/JP2024129084A/ja
Application granted granted Critical
Publication of JP7513530B2 publication Critical patent/JP7513530B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571532A 2018-06-22 2019-06-24 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法 Active JP7513530B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103927A JP2024129084A (ja) 2018-06-22 2024-06-27 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688921P 2018-06-22 2018-06-22
US62/688,921 2018-06-22
PCT/EP2019/066700 WO2019243636A1 (en) 2018-06-22 2019-06-24 Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103927A Division JP2024129084A (ja) 2018-06-22 2024-06-27 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2021528439A JP2021528439A (ja) 2021-10-21
JP2021528439A5 true JP2021528439A5 (cg-RX-API-DMAC7.html) 2022-07-01
JP7513530B2 JP7513530B2 (ja) 2024-07-09

Family

ID=67139695

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571532A Active JP7513530B2 (ja) 2018-06-22 2019-06-24 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法
JP2024103927A Pending JP2024129084A (ja) 2018-06-22 2024-06-27 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103927A Pending JP2024129084A (ja) 2018-06-22 2024-06-27 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法

Country Status (5)

Country Link
US (1) US12275797B2 (cg-RX-API-DMAC7.html)
EP (1) EP3810194A1 (cg-RX-API-DMAC7.html)
JP (2) JP7513530B2 (cg-RX-API-DMAC7.html)
MA (1) MA52951A (cg-RX-API-DMAC7.html)
WO (1) WO2019243636A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
AR127743A1 (es) 2021-09-06 2024-02-28 Genmab Bv Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US20120189618A1 (en) 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
WO2015116729A2 (en) * 2014-01-28 2015-08-06 Emergent Product Development Seattle, Llc Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Fcタンパク質
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
AU2019354105A1 (en) 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies

Similar Documents

Publication Publication Date Title
JP2024056938A5 (cg-RX-API-DMAC7.html)
JP2021524256A5 (cg-RX-API-DMAC7.html)
AU2022228155A1 (en) Antibodies to cd40
JP2021527431A5 (cg-RX-API-DMAC7.html)
EP3603672B1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016285920A1 (en) Antibodies to CD40 with enhanced agonist activity
JP2022533538A5 (cg-RX-API-DMAC7.html)
WO2018210793A2 (en) ANTI-SIRPα ANTIBODIES
JP2020516309A5 (cg-RX-API-DMAC7.html)
TW201902512A (zh) 治療方法
JP2017507953A5 (cg-RX-API-DMAC7.html)
JP6534074B2 (ja) 抗体
EP3880707A1 (en) HUMANIZED ANTI-SIRPa ANTIBODIES
JP2021522303A5 (cg-RX-API-DMAC7.html)
EP4146698A1 (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
JP7486616B2 (ja) Btla抗体
JP2023547506A5 (cg-RX-API-DMAC7.html)
JP2018533569A5 (cg-RX-API-DMAC7.html)
JP2024533457A5 (cg-RX-API-DMAC7.html)
WO2018044172A1 (en) Cd20 antibodies
JP2021524451A (ja) 最適化済みgp41結合分子及びその使用
JP2022548881A5 (cg-RX-API-DMAC7.html)
WO2025085857A1 (en) Sirp antibodies for treatment of cancer
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2024188790A1 (en) Lung cancer targeting human antibodies and therapeutic uses thereof